Ganoderma lucidum (reishi mushroom) for cancer treatment
Jin X, Ruiz Beguerie J, Sze DM, Chan GCF
Published in Cochrane Database of Systematic Reviews
Key Findings
Patients given Ganoderma alongside chemotherapy were more likely to respond and showed increased NK-cell activity, but no survival benefit was demonstrated.
Conclusions
Reishi may be used as an adjunct to conventional care but is not supported as a sole cancer treatment.
Limitations
Few trials, methodological weaknesses and high risk of bias in the included studies.
Supplements Studied
Quality-of-life measures improved with adjunctive Ganoderma, though sleep was not a primary endpoint.
Outcomes Measured
Quality-of-life measures improved with adjunctive Ganoderma, though sleep was not a primary endpoint.
Ganoderma increased NK-cell activity and improved quality-of-life measures as an adjunct, without survival benefit.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.